Navigation Links
Current and Emerging Therapies Have No Advantage Over Pfizer's Lyrica in Their Effect on Patients' Quality of Life in the Treatment of Diabetic Neuropathy
Date:3/13/2008

However, Owing to Safety and Delivery End Points, Drugs from Eli Lilly and Boehringer Ingelheim Will Remain as the Gold Standard Treatments, According

to a New Report from Decision Resources

WALTHAM, Mass., March 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug's effect on a patient's quality of life is the attribute that most influences neurologists' prescribing decisions in the treatment of diabetic neuropathy. Clinical data and expert opinion show that current and emerging therapies have no advantage in this attribute over Pfizer's Lyrica.

The new report entitled Diabetic Neuropathy: Moderate Pain Relief No Longer Enough-Physicians Expect More-Effective Therapies finds that if an agent offering pain relief superior to that of sales-leading Lyrica were to be launched, it would earn a 33% patient share, according to surveyed neurologists. The report also finds that, although Lyrica is the sales leader in the diabetic neuropathy drug market, the current and future gold standard treatment for the indication is Eli Lilly's Cymbalta/Boehringer Ingelheim's Xeristar.

Although the efficacy of Cymbalta/Xeristar is equal to that of Lyrica, Cymbalta/Xeristar outscores Lyrica in safety and delivery end points. In particular, Cymbalta/Xeristar does not cause weight gain and is associated with less symptoms of dizziness than Lyrica.

"Based on available data and expert opinion, we do not expect any therapy under development to displace Cymbalta/Xeristar as the clinical gold standard for diabetic neuropathy," said Marcus Bain, Ph.D., analyst at Decision Resources. "Although some therapies in development hold promise, most of them earned inferior scores in efficacy, safety and tolerability, and/or delivery features when compared with Cymbalta/Xeristar."

About the Report

Diabetic Neuropathy: Moderate Pain
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
2. Glass Lewis Recommends Arrow Shareholders Vote on the White Proxy Card for Merger With Teleflex and for Current Board of Directors at Arrow Annual Meeting
3. Arrow International Sends Letter Reminding Shareholders to Vote White Proxy Card in Support of Teleflex Merger and Election of Current Board of Directors
4. Morris Animal Foundation 2008 Sponsorship Guide Available, Details Current Animal Health Studies
5. Experimental drug boosts survival in recurrent ovarian cancer
6. Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees
7. Stop eating for two: obese moms-to-be should gain less weight than currently recommended
8. Switching to MA Coverage Unlikely for Current Beneficiaries With MediGap or Medicare Only
9. The Current Recall of Boy Scouts of Americas Plastic Badges Does Not Affect Embroidered Insignia, Badges & Awards Produced by Lion Brothers Company Inc.
10. Purified Fish Oil Concentrates Offer Solution to Current Seafood Controversy for Pregnant and Breastfeeding Women!
11. ALEVE-D(R) Sinus & Cold Offers Option for the More Than 50% of Consumers Not Satisfied with Current Sinus Medication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... Raton, Fl (PRWEB) , ... August 30, 2015 , ... ... InHealth Media. Nutritional Products International and InHealth media is a global sales and ... , “We are extremely pleased to continue our business relationship with Mr. Reid Eckert, ...
(Date:8/30/2015)... ... 30, 2015 , ... Nutritional Products International ( http://www.nutricompany.com ) ... Assistant to CEO Mitch Gould for Nutritional Products International. Through all methods ... Kathleen graduated from Florida State University with a Bachelor of Science in Business ...
(Date:8/29/2015)... ... ... Rio Salado College President Chris Bustamante announced on Aug. 19 ... Initiatives and Information Services. O’Shea, who has served Rio Salado for the last two ... through innovative technologies and strategies. , “I am very proud to be able to ...
(Date:8/29/2015)... ... August 30, 2015 , ... Electronic ... 1:30 p.m. – 3:00 p.m. EDT, http://www.fdanews.com/electronicinformedconsent , The simple fact ... handwritten signature. , Clinical trial sites can now use audio, video ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... inventors from Miller Place, N.Y. "I specialize in manual therapy, and my invention ... it can be used for additional muscle dysfunction throughout the body." , They ...
Breaking Medicine News(10 mins):Health News:Nutrition Guru Continues Relationship With Renowned Health and Wellness Company 2Health News:NPI Appoints New Executive Assistant To CEO 2Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 2Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 3Health News:FDAnews Announces — Electronic Informed Consent for Clinical Trials: Best Practices Webinar, Sept. 15, 2015 4Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2
... April 9 Healthcare,workers at Tri-City Medical Center ... State Mediation & Conciliation Service,confirmed that caregivers strongly ... union authorization cards., TCMC caregivers become members ... thousands of other healthcare workers who have achieved ...
... PARK RIDGE, Ill., April 9 A study published ... Clinical Nutrition(i) suggests,an association between high egg consumption and ... not provide an explanation.,The researchers, Djousse and Gaziano, analyzed ... physicians over a 20 year period., The fact ...
... protein it expresses may cause some cases of the disease ... change in one gene, called CHI3L1, can increase a person,s ... causes the gene to release high levels of a protein ... been associated with an increased risk of asthma in past ...
... YORK, April 9 Duane Reade Holdings, Inc. today,announced ... has resigned from the Company to assume a senior ... resignation,will be effective on April 17, 2008., The ... Marketing Officer,position and will move swiftly to identify another ...
... stopped. But it can be predicted, and new research from ... lead healthier lives as a result. , Researchers have developed ... bodys bones. It reveals that the speed of physical aging ... (OSS), this new marker can be used by doctors ...
... N.J., April 9 Defined Health has,announced ... its 8th annual Therapeutic,Insight conference. Therapeutic Insight ... - 30, 2008, at The Westin New ... and key opinion leaders will discuss relevant,pharma/biotech ...
Cached Medicine News:Health News:North County Caregivers Join United Healthcare Workers 2Health News:Statement by the American Egg Board and Egg Nutrition Center on AJCN Study on Egg Consumption 2Health News:Statement by the American Egg Board and Egg Nutrition Center on AJCN Study on Egg Consumption 3Health News:Researchers Find Gene Mutation That Increases Asthma Risk 2Health News:Researchers Find Gene Mutation That Increases Asthma Risk 3Health News:Duane Reade Holdings, Inc. Announces Resignation of Chief Marketing Officer 2Health News:How fast you'll age is written in the bones, TAU research finds 2Health News:Defined Health Announces Final Speaker Roster and Agenda for Therapeutic Insight 2008 2Health News:Defined Health Announces Final Speaker Roster and Agenda for Therapeutic Insight 2008 3
(Date:8/28/2015)... Aug. 28, 2015 ... the addition of the "Investigation Report on ... offering. Developed by Pharmacia & Upjohn ... agonist which effectively reduces intraocular pressure. As the ... (under the trade name of Xalatan) entered ...
(Date:8/28/2015)... -- Perrigo Company plc ("Perrigo") (NYSE: PRGO ; TASE) ... leading OTC brands from GSK in an all cash ... clear demonstration of Perrigo,s unique ability to maximize brand ... 36 countries.  Perrigo Chairman, President and ... excited to complete this transaction, which clearly demonstrates our ...
(Date:8/28/2015)... Massachusetts y LONDRES, 28 de agosto ... AEX: PHIA) anunció hoy su participación en el  ... exhibirá sus soluciones cardiológicas más recientes y novedosas, ... Cardiovascular, que conectan a las personas y la ... de ayudar a diagnosticar, guiar los tratamientos y ...
Breaking Medicine Technology:China Latanoprost Market Investigation Report 2015-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5
... Medical, Inc. (Solta) (Nasdaq: SLTM ), ... today announced that Medicis Technologies Corporation (formerly LipoSonix, ... has received U.S. Food and Drug Administration (FDA) ... indicated for non-invasive waist circumference reduction. The LipoSonix ...
... SPRING, Md., Oct. 24, 2011 The U.S. ... generic versions of Zyprexa (olanzapine tablets) and Zyprexa ... and bipolar disorder. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ... and disabling brain disorder. About 1 percent of ...
Cached Medicine Technology:Solta Medical Reports FDA Clearance Received for Second Generation LipoSonix® System 2Solta Medical Reports FDA Clearance Received for Second Generation LipoSonix® System 3Solta Medical Reports FDA Clearance Received for Second Generation LipoSonix® System 4Solta Medical Reports FDA Clearance Received for Second Generation LipoSonix® System 5FDA Approves First Generic Olanzapine to Treat Schizophrenia, Bipolar Disorder 2FDA Approves First Generic Olanzapine to Treat Schizophrenia, Bipolar Disorder 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: